HTN Guide vs NoduleRisk

HTN Guide puts the AHA/ACC 2025 Hypertension Guidelines at your fingertips — a fast clinical reference for physicians, nurse practitioners, and clinical pharmacists at the point of care. Important: HTN Guide is intended for educational and reference use by licensed healthcare professionals only. It is not a medical device, does not diagnose, and does not replace clinical judgment. Always apply individual patient assessment when making treatment decisions. What HTN Guide presents: Enter a patient's blood pressure, age, sex, 10-year PREVENT CVD risk, and comorbidities. HTN Guide presents the relevant AHA/ACC 2025 guideline recommendations: - Blood pressure stage (Normal, Elevated, Stage 1, Stage 2, or Hypertensive Crisis) - Whether current guidelines support drug therapy initiation - First-line drug class options for the patient's profile - Compelling indication drugs for Heart Failure, CKD, Diabetes, post-MI, and Stroke/TIA - Two-drug initiation flag when BP is significantly above goal - Lifestyle modification recommendations with evidence-based BP reduction estimates - Hypertensive Crisis triage guidance (Emergency vs. Urgency) Key features: - Built-in AHA PREVENT 10-year CVD risk calculator — tap "Calculate →" on the form - Patient history — last 10 evaluations saved locally on your device - Dark mode support - Works offline Privacy first: - No patient identifiers required — clinical parameters only - Nothing transmitted off-device — all data stays on your phone - No account, no login, no analytics on patient data

NoduleRisk is a clinical decision support tool for physicians evaluating pulmonary nodule malignancy risk. It computes probability estimates and management guidance across five validated models simultaneously. MODELS INCLUDED • Mayo Clinic (ACCP) — logistic regression model for incidentally detected nodules • Brock (BTS/PanCan) — recommended for screening populations; validated in the Pan-Canadian Lung Cancer Screening Study • Herder (BTS) — incorporates FDG-PET/CT uptake when available • BIMC (Bayesian) — Bayesian likelihood ratio model with adjustable prior probability; displays individual likelihood ratio contributions • Fleischner 2017 — guideline-based follow-up recommendations with automatic risk stratification FEATURES • Multi-nodule evaluation (up to 6 nodules per patient) • Volume doubling time calculation from serial CT measurements • Risk-stratified management recommendations for each model • Applicability warnings when inputs are outside model validation ranges • Clinical context adjustments for screening and biopsy-referred populations • Fully offline — no data is transmitted or stored IMPORTANT NoduleRisk is intended for use by qualified clinicians as a decision support aid only. Results must be interpreted in the context of the full clinical picture and do not substitute for institutional guidelines, multidisciplinary team discussion, or clinical judgment.